Insulet Corporation

Insulet's P/E of 49.0 towers over the med-device sector median while its RSI of 32.1 signals oversold conditions—a classic tension that suggests either capitulation-driven opportunity or justified repricing of growth expectations. The stock trades nowhere near its 52-week high despite the sharp RSI dip, implying recent selling pressure has been decisive rather than panicked. With short interest at just 4.4%, there's minimal squeeze potential, and the $13.6B market cap commands respect in surgical instruments. The elevated multiple paired with a legitimately oversold technicals and modest short covering demand creates asymmetry—either the market has overshot downside on temporary headwinds, or the valuation never justified the growth thesis to begin with.